Barry Richard's Form 4 filing
Filana Therapeutics, Inc. (FLNA) · filed Oct 1, 2026
- Accession no.
- 0001437749-26-031654
- Filed
- Oct 1, 2026, 7:57 AM ET
- Trade date
- Sep 29-30, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $278.1K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Barry RichardCIK 0001562371 | Director, Officer (President & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The purchase reported in column 4 is a weighted average price. The shares were purchased in multiple open market transactions at prices ranging from $0.86 to $0.94 per share. The reporting person undertakes to provide to Filana, any security holder of Filana or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F2
The purchase reported in column 4 is a weighted average price. The shares were purchased in multiple open market transactions at prices ranging from $0.91 to $0.93 per share. The reporting person undertakes to provide to Filana, any security holder of Filana or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.